Navigation Links
SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
Date:4/16/2008

Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns

SuperGen, Inc.

SVP, Corporate Communications & Business Development

Tel: (925) 560-0100

E-mail: tenns@supergen.com

Mary M. Vegh

SuperGen, Inc.

Manager, Investor Relations

Tel: (925) 560-2845

E-mail: mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Data Show SuperGens MP-470 is Safe in Humans
2. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
3. SuperGens MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib
4. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
5. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
6. Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization
7. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
8. Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
9. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
10. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
11. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
(Date:1/22/2015)... privately held medical device company, announced today that it ... Corporation (Tokyo Stock Exchange TYO: 8001) to sell its ... in Japan . ViewRay,s technology, the ... MRI-guided radiation therapy system that images and treats cancer ...
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... 2012  BioParadox, Inc., a regenerative medicine company pioneering ... a strategic alliance with Fogarty Institute for Innovation.  ... working with the Fogarty Institute for Innovation known ... patients with challenging problems.  The Fogarty Institute,s unique ...
... 2, 2012 Synthetic Genomics, Inc. (SGI), a ... to solve a variety of global needs, and ... in production and supply of oligonucleotides, today jointly ... to manufacture, market, and commercialize small synthetic gene ...
Cached Medicine Technology:BioParadox Announces Partnership with Fogarty Institute for Innovation 2Synthetic Genomics, Inc. and Integrated DNA Technologies, Inc. Sign Agreement to Manufacture, Market, and Commercialize Small Synthetic Gene Products Using SGI Technology 2
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to announce ... Services at North Carolina State’s College of Veterinary Medicine ... Award for Distinguished Volunteer Service—the organization’s highest award. ... of volunteer experts to direct its work to improve ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... TripAdvisor as the number one best large hotel for families ... world for their annual Travelers’ Choice Awards. , TripAdvisor ... website is home to millions of unbiased and honest traveler ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2
... March 16 Insulet Corporation (Nasdaq: ... technology with its OmniPod(R) Insulin Management System, today ... with leading healthcare investor, Deerfield Management Company, to ... financing through a flexible credit facility."We are pleased ...
... /PRNewswire-Aisia-FirstCall/ -- China Nepstar,Chain Drugstore Ltd. (NYSE: ... the,largest drugstore chain in China based on the ... Board of Directors has declared a cash,dividend of ... million, which amounts to the sum of the ...
... affected, studies find , , SUNDAY, March 15 (HealthDay News) -- ... burden on a family,s finances and even its vacation plans. ... Washington, D.C., at the annual meeting of the American Academy ... can have a wide impact on a family,s quality of ...
... ARLINGTON, Va., March 14 The Generic Pharmaceutical Association ... and CEO Kathleen Jaeger regarding the nomination of Dr. ... Deputy Commissioner of the U.S. Food and Drug Administration ... on the critical issues facing the Agency as it ...
... lens (ICL) procedure, Dr. Alan R. Faulkner with Aloha Laser Vision ... the only effective way to reduce dependence on corrective eyewear. ... ... have undergone LASIK laser vision correction surgery since its popularity started ...
... NCCN Clinical Practice Guidelines in Oncology(TM) for Primary ... to the NCCN Guidelines for Non-Hodgkin,s Lymphomas at ... Guidelines were written to distinguish Primary B-Cell Lymphomas ... treatment recommendations. Andrew D. Zelenetz, MD, PhD, and ...
Cached Medicine News:Health News:Insulet Receives $60 Million Funding Commitment 2Health News:Insulet Receives $60 Million Funding Commitment 3Health News:Insulet Receives $60 Million Funding Commitment 4Health News:Insulet Receives $60 Million Funding Commitment 5Health News:China Nepstar Chain Drugstore Announces Dividend 2Health News:China Nepstar Chain Drugstore Announces Dividend 3Health News:Child's Food Allergies Take Toll on Family Plans 2Health News:GPhA Statement on Nomination of Dr. Margaret Hamburg as Commissioner and Dr. Joshua Sharfstein as Deputy Commissioner of FDA 2Health News:Honolulu Opthalmologist Alan R. Faulkner, MD Discusses Advantages of Implantable Contact Lenses (ICL) over LASIK Laser Vision Correction 2Health News:Honolulu Opthalmologist Alan R. Faulkner, MD Discusses Advantages of Implantable Contact Lenses (ICL) over LASIK Laser Vision Correction 3Health News:New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guidelines for Non-Hodgkin's Lymphomas 2Health News:New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guidelines for Non-Hodgkin's Lymphomas 3Health News:New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guidelines for Non-Hodgkin's Lymphomas 4
For the quantitative in vitro determination of Triglycerides in serum and plasma....
The CK method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
Medicine Products: